Embla Medical Hf · OMXCOP:EMBLA
Embla Medical Hf — Q3 2025 Earnings Presentation
12 slides from Embla Medical Hf's earnings presentation, Oct 21, 2025
Slide 1: Q3 2025 Conference Call
A leading global provider of innovative mobility solutions Q3 2025 Conference Call Sveinn Sölvason, President and CEO G. Arna Sveinsdottir, CFO October 21, 2025 0
Slide 2: Key Highlights for Q3 2025
Key Highlights for Q3 2025 Q3 Performance & Guidance Strategic initiatives External Organic sales growth Reported sales growth (USD) Streifeneder ortho.production Section 232 related to MedTech ✓ Closing of the majority +11% ▪ Several factors remain uncertain +7% investment (51% of shares) ✓ Acquisi
Slide 3: Growth in Q3 2025 was driven by solid growth across all regions
Growth in Q3 2025 was driven by solid growth across all regions mainly driven by Prosthetics & Neuro Orthotics APAC Q3: APAC+18% Americas Q3: +5% 6% 3% 13% 3% 18% 7% 5% 2% 3% 20 -1% 17 17 18 16 100 107 102 104 85 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 EMEA Q3: +7% Sales (USDm) %
Slide 4: Prosthetics & Neuro Orthotics sales
Prosthetics & Neuro Orthotics sales % of total sales in Q3 Year-to-date sales Year-to-date growth Highlights ▪ EMEA: Continued strong momentum in EMEA across most markets driven by volume growth and solid 53% uptake across most product categories; especially in 372 10% Bionics and Feet solutions sup
Slide 5: Bracing & Supports sales
Bracing & Supports sales % of total sales in Q3 Year-to-date sales Year-to-date growth Highlights ▪ EMEA: Sales in Bracing & Supports were soft in EMEA during Q3 with some markets showing good performance but offset by softer performance in 111 -1% other markets USD million organic growth ▪ Americas
Slide 6: Patient Care sales
Patient Care sales % of total sales in Q3 Year-to-date sales Year-to-date growth Highlights ▪ EMEA: Mixed performance for the quarter with strong performance in selected markets but offset 31% by softer sales in some of our larger markets 217 0% ▪ Americas: Good performance in selected territories U
Slide 7: EBITDA margin expanding by 1%-points in 9M'25
EBITDA margin expanding by 1%-points in 9M’25 to 21% (vs 20% in 9M’24) despite unfavorable FX; Expansion driven by continued cost discipline in SG&A Gross Profit and Gross Profit margin Highlights USD million ▪ Net sales: 7% organic growth in the quarter and 11% reported growth with 63% 63% 63% 63%
Slide 8: Cash flow and leverage
Cash flow and leverage Capital expenditures and % of sales Free cash flow and % of sales Net Interest-Bearing Debt and Leverage USD million on actual rate USD million on actual rate USD million on actual rate 10 472 460 460 38 437 9 414 8 8 33 34 6 16% 2.8x 15% 15% 2.6x 2.5x 2.5x 2.3x 2.4x 12 4.4% 2
Slide 9: 2025 Guidance
2025 Guidance Guidance as of Guidance as of YTD 2025 Oct 21 2025 July 22 2025 Sales growth 5-6% 5% 5-6% Organic EBITDA margin Before special 20-21% 21% 20-21% items For modeling purposes: Special items None None None In USD million CAPEX 3-4% 4% 3-4% % of sales Tax 23-24% 24% 23-24% Effective tax ra
Slide 10: Q&A: Key messages from Q3 2025
Q&A Key messages from Q3 2025 1. Growth picked up in Q3 as expected, driven by double-digit growth in Prosthetics & Neuro Orthotics. - The solid momentum in EMEA continues and growth in Americas was strong following a soft start to the year 2. Well on track with our strategic initiatives: ✓ Closed a
Slide 11: Contact our Investor Relations
Contact our Investor Relations Financial calendar and events Oct 21, 2025 Interim report Q3 2025 Oct 21, 2025 Q3 2025 HCA Capital virtual presentation and Q&A Oct 22, 2025 Q3 2025 Investor Road Show, Copenhagen (Danske Bank) Investor Relations Oct 22-23, 2025 Q3 2025 Investor Road Show, Benelux (DNB
Slide 12: Forward-looking statement
Forward-looking statement This presentation contains forward-looking statements, which reflect the Management’s current views with respect to certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there is no assura